FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, more specifically to obtaining immunogenic mutant toxins Clostridium difficile; it can be used in medicine for the treatment of C. difficile infection in a mammal. A mutant toxin C. difficile containing amino acid sequence SEQ ID NO: 6, wherein methionine residue in the position 1 is probably absent, a nucleic acid encoding it, a composition containing it, antibodies to it, and a composition containing the specified antibodies are proposed.
EFFECT: invention allows inducing effectively neutralizing antibodies against the toxin B C. difficile.
33 cl, 25 dwg, 61 tbl, 45 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS RELATED TO MUTANT TOXIN CLOSTRIDIUM DIFFICILE AND THEIR APPLICATION METHODS | 2017 |
|
RU2773880C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| MUTANT NITRILE HYDRATASE, NUCLEIC ACID WHICH ENCODES SAID MUTANT NITRILE HYDRATASE, EXPRESSION VECTOR AND TRANSFORMANT CONTAINING SAID NUCLEIC ACID, METHOD OF PRODUCING SAID MUTANT NITRILE HYDRATASE AND METHOD OF PRODUCING AMIDE COMPOUND | 2017 |
|
RU2736086C1 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER | 2020 |
|
RU2821999C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
